247 related articles for article (PubMed ID: 37418057)
1. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study.
Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK;
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057
[TBL] [Abstract][Full Text] [Related]
2. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of lenalidomide plus dexamethasone vs. bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma.
Usmani SZ; Cavenagh JD; Belch AR; Hulin C; Basu S; White D; Nooka A; Ervin-Haynes A; Yiu W; Nagarwala Y; Berger A; Pelligra CG; Guo S; Binder G; Gibson CJ; Facon T
J Med Econ; 2016; 19(3):243-58. PubMed ID: 26517601
[TBL] [Abstract][Full Text] [Related]
4. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
[TBL] [Abstract][Full Text] [Related]
5. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT).
Dimopoulos MA; Cavo M; Mateos MV; Facon T; Heeg B; van Beekhuizen S; Gebregergish SB; Nair S; Pisini M; Lam A; Slavcev M
Leuk Lymphoma; 2020 Mar; 61(3):714-720. PubMed ID: 31686559
[TBL] [Abstract][Full Text] [Related]
6. First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials.
Larocca A; Mina R; Offidani M; Liberati AM; Ledda A; Patriarca F; Evangelista A; Spada S; Benevolo G; Oddolo D; Innao V; Cangiolosi C; Bernardini A; Musto P; Amico V; Fraticelli V; Paris L; Giuliani N; Falcone AP; Zambello R; De Paoli L; Romano A; Palumbo A; Montefusco V; Hájek R; Boccadoro M; Bringhen S
Haematologica; 2020 Apr; 105(4):1074-1080. PubMed ID: 31248973
[TBL] [Abstract][Full Text] [Related]
7. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
8. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Knop S; Doyen C; Lucio P; Nagy Z; Pour L; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Yoon SS; Iosava G; Fujisaki T; Garg M; Iida S; Bladé J; Ukropec J; Pei H; Van Rampelbergh R; Kudva A; Qi M; San-Miguel J
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):785-798. PubMed ID: 34344638
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
Hungria V; Martínez-Baños DM; Mateos MV; Dimopoulos MA; Cavo M; Heeg B; Garcia A; Lam A; Machnicki G; He J; Fernandez M
Adv Ther; 2020 Dec; 37(12):4996-5009. PubMed ID: 33067698
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials.
Gentile M; Magarotto V; Offidani M; Musto P; Bringhen S; Teresa Petrucci M; Gay F; Larocca A; Uccello G; Petrungaro A; Vigna E; Greco R; Grazia Recchia A; Tripepi G; Ria R; Di Raimondo F; Palumbo A; Morabito F
Am J Hematol; 2017 Mar; 92(3):244-250. PubMed ID: 28006855
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database.
Jimenez-Zepeda VH; Venner C; McCurdy A; Masih-Khan E; Atenafu EG; Sebag M; Stakiw J; Song K; LeBlanc R; Reiman T; Louzada M; Kotb R; Gul E; Reece D
Br J Haematol; 2021 May; 193(3):532-541. PubMed ID: 33559897
[TBL] [Abstract][Full Text] [Related]
12. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Facon T; San-Miguel J; Dimopoulos MA; Mateos MV; Cavo M; van Beekhuizen S; Yuan Z; Mendes J; Lam A; He J; Ammann E; Kumar S
Adv Ther; 2022 May; 39(5):1976-1992. PubMed ID: 35246820
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Sandecká V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Heindorfer A; Pavlíček P; Sýkora M; Jungová A; Kessler P; Wróbel M; Starostka D; Ullrychová J; Stejskal L; Štork M; Straub J; Pika T; Brožová L; Ševčíková S; Maisnar V; Hájek R
Eur J Haematol; 2021 Oct; 107(4):466-474. PubMed ID: 34272773
[TBL] [Abstract][Full Text] [Related]
14. Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.
Mateos MV; Martínez-López J; Hernández MT; Ocio EM; Rosiñol L; Martínez R; Teruel AI; Gutiérrez NC; Martín Ramos ML; Oriol A; Bargay J; Bengoechea E; González Y; Pérez de Oteyza J; Gironella M; Encinas C; Martín J; Cabrera C; Paiva B; Cedena MT; Puig N; Bladé J; Lahuerta JJ; San-Miguel J
Blood; 2016 Jan; 127(4):420-5. PubMed ID: 26500339
[TBL] [Abstract][Full Text] [Related]
15. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Lee JH; Moreau P; Niesvizky R; Dimopoulos M; Hajek R; Pour L; Jurczyszyn A; Qiu L; Klippel Z; Zahlten-Kumeli A; Osman M; Paiva B; San-Miguel J
Blood; 2019 May; 133(18):1953-1963. PubMed ID: 30819926
[TBL] [Abstract][Full Text] [Related]
16. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis.
Ramasamy K; Dhanasiri S; Thom H; Buchanan V; Robinson S; D'Souza VK; Weisel K
Leuk Lymphoma; 2020 Mar; 61(3):668-679. PubMed ID: 31709875
[TBL] [Abstract][Full Text] [Related]
17. Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ishida T; Kimura H; Ozaki S; Kubo K; Sunami K; Takezako N; Fujita H; Hayashi T; Kiguchi T; Ohashi K; Yamamoto S; Takamatsu H; Kosugi H; Ohta K; Sakai R; Handa H; Kondo S; Abe Y; Omoto E; Mitani K; Morita S; Murakami H; Shimizu K
Ann Hematol; 2020 May; 99(5):1063-1072. PubMed ID: 32248251
[TBL] [Abstract][Full Text] [Related]
18. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
[TBL] [Abstract][Full Text] [Related]
19. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials.
Mateos MV; Oriol A; Martínez-López J; Teruel AI; Bengoechea E; Palomera L; de Arriba F; Esseltine DL; Cakana A; Pei L; van de Velde H; Miguel JS
Ann Hematol; 2016 Dec; 95(12):2033-2041. PubMed ID: 27738789
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.
Mateos MV; Richardson PG; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Esseltine DL; Liu K; Cakana A; van de Velde H; San Miguel JF
J Clin Oncol; 2010 May; 28(13):2259-66. PubMed ID: 20368561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]